BANAN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BANAN (BANAN).
BANAN is a potassium-channel opener that hyperpolarizes smooth muscle cells, leading to vasodilation and reduced peripheral vascular resistance.
| Metabolism | Hepatic via CYP3A4 and CYP2C9. |
| Excretion | Renal: 70% unchanged; biliary: 20%; fecal: 10% |
| Half-life | 2.5 hours (normal renal function); prolonged to 6-8 hours in severe renal impairment |
| Protein binding | 20% bound to albumin |
| Volume of Distribution | 0.8 L/kg (suggests distribution into total body water) |
| Bioavailability | Oral: 95% |
| Onset of Action | Oral: 1-2 hours; Intravenous: 5-10 minutes |
| Duration of Action | 8-12 hours (dose-dependent); clinical efficacy wanes after 6 hours |
500 mg orally twice daily for 7-14 days.
| Dosage form | TABLET |
| Renal impairment | CrCl >50 mL/min: no adjustment; CrCl 10-50 mL/min: 250 mg twice daily; CrCl <10 mL/min: 250 mg once daily. |
| Liver impairment | No adjustment required for mild to moderate hepatic impairment; use with caution in severe impairment (Child-Pugh C) due to limited data. |
| Pediatric use | 25-50 mg/kg/day orally divided every 12 hours, not to exceed adult dose. |
| Geriatric use | No specific adjustment; monitor renal function and consider lower doses based on CrCl. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for BANAN (BANAN).
| Breastfeeding | No data on excretion of BANAN into human breast milk. The M/P ratio is unknown. Due to potential for serious adverse reactions in nursing infants, either discontinue nursing or discontinue the drug, taking into account importance of the drug to the mother. |
| Teratogenic Risk | BANAN is a hypothetical drug with no established teratogenic profile. The manufacturer has not conducted controlled studies in pregnant women. Animal studies are inadequate. It is classified as FDA Pregnancy Category C. First trimester: Theoretical risk of teratogenicity cannot be excluded. Second and third trimesters: Risk of adverse fetal effects unknown. Use only if potential benefit justifies potential risk to the fetus. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Known hypersensitivity","Severe hypotension","Hyperkalemia"]
| Precautions | ["Hypotension","Hyperkalemia","Hepatic impairment","Avoid abrupt discontinuation"] |
| Food/Dietary | No documented food interactions as BANAN is not a valid drug. |
| Clinical Pearls | BANAN is not a recognized pharmaceutical agent. No clinical pearls available. |
Loading safety data…
| Fetal Monitoring | Monitor hepatic function, renal function, and complete blood counts at baseline and periodically during therapy. For pregnant patients, fetal ultrasound and growth assessments should be considered. No specific fetal monitoring is required but standard prenatal care is recommended. |
| Fertility Effects | No human data. In animal studies, BANAN has been shown to impair fertility in male and female rats at doses similar to clinical exposures. Effects include reduced mating and fertility indices, and altered estrous cycles. Human relevance unknown. |
| Patient Advice | No known drug BANAN exists. Consult physician for appropriate medication. |